Keyphrases
Advanced Renal Cell Carcinoma
100%
Immune Checkpoint Blockade
100%
Selinexor
100%
Nivolumab
69%
Ipilimumab
30%
Treatment-related Adverse Events
23%
Objective Response Rate
15%
Advanced Malignancies
7%
Systemic Therapy
7%
Stable Disease
7%
Median Overall Survival
7%
Neutropenia
7%
Tumor Suppressor
7%
Clinical Activity
7%
Best Response
7%
Progression-free Survival
7%
Twice Daily
7%
Clinical Trials
7%
Median Progression-free Survival
7%
Safety Profile
7%
Nuclear Proteins
7%
Preclinical Data
7%
Exportin-1
7%
Hyponatremia
7%
Trial Registration
7%
Clear Cell Renal Cell Carcinoma (ccRCC)
7%
Checkpoint Blockade
7%
Multi-arm
7%
Response to Immunotherapy
7%
Nivolumab Plus Ipilimumab
7%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Immune Checkpoint Blockade
100%
Selinexor
100%
Nivolumab
76%
Ipilimumab
38%
Adverse Event
23%
Progression Free Survival
15%
Arm
15%
Cancer
7%
Diseases
7%
Systemic Therapy
7%
Clinical Trial
7%
Overall Survival
7%
Immunotherapy
7%
Neutropenia
7%
Clear Cell
7%
Tumor Suppressor Protein
7%
Hyponatremia
7%
Nuclear Protein
7%
Thromboembolism
7%
Exportin 1
7%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Selinexor
100%
Nivolumab
76%
Ipilimumab
38%
Adverse Event
23%
Progression Free Survival
15%
Diseases
7%
Tumor Suppressor Protein
7%
Overall Survival
7%
Clinical Trial
7%
Neutropenia
7%
Immunotherapy
7%
Thromboembolism
7%
Hyponatremia
7%
Nuclear Protein
7%
Exportin 1
7%